keyword
https://read.qxmd.com/read/38637829/ace-inhibitors-and-angiotensin-receptor-blockers-differentially-alter-the-response-to-angiotensin-ii-treatment-in-vasodilatory-shock
#1
JOURNAL ARTICLE
Daniel E Leisman, Damian R Handisides, Laurence W Busse, Mark C Chappell, Lakhmir S Chawla, Michael R Filbin, Marcia B Goldberg, Kealy R Ham, Ashish K Khanna, Marlies Ostermann, Michael T McCurdy, Christopher D Adams, Tony N Hodges, Rinaldo Bellomo
BACKGROUND: Angiotensin-converting enzyme inhibitor (ACEi) and angiotensin receptor blockers (ARB) medications are widely prescribed. We sought to assess how pre-admission use of these medications might impact the response to angiotensin-II treatment during vasodilatory shock. METHODS: In a post-hoc subgroup analysis of the randomized, placebo-controlled, Angiotensin Therapy for High Output Shock (ATHOS-3) trial, we compared patients with chronic angiotensin-converting enzyme inhibitor (ACEi) use, and patients with angiotensin receptor blocker (ARB) use, to patients without exposure to either ACEi or ARB...
April 18, 2024: Critical Care: the Official Journal of the Critical Care Forum
https://read.qxmd.com/read/38555976/dysfunction-of-the-renin-angiotensin-aldosterone-system-in-human-septic-shock
#2
JOURNAL ARTICLE
Christopher L Schaich, Daniel E Leisman, Marcia B Goldberg, Micheal R Filbin, Ashish K Khanna, Mark C Chappell
Sepsis and septic shock are global healthcare problems associated with mortality rates of up to 40% despite optimal standard-of-care therapy and constitute the primary cause of death in intensive care units worldwide. Circulating biomarkers of septic shock severity may represent a clinically relevant approach to individualize those patients at risk for worse outcomes early in the course of the disease, which may facilitate early and more precise interventions to improve the clinical course. However, currently used septic shock biomarkers, including lactate, may be non-specific and have variable impact on prognosis and/or disease management...
March 29, 2024: Peptides
https://read.qxmd.com/read/38475822/the-scientific-rationale-and-study-protocol-for-the-dpp3-angiotensin-ii-and-renin-kinetics-in-sepsis-dark-sepsis-randomized-controlled-trial-serum-biomarkers-to-predict-response-to-angiotensin-ii-versus-standard-of-care-vasopressor-therapy-in-the-treatment
#3
JOURNAL ARTICLE
J Pedro Teixeira, David Perez Ingles, Jordan B Barton, James T Dean, Pablo Garcia, Susan J Kunkel, Preeyaporn Sarangarm, Natalie K Weiss, Christopher L Schaich, Laurence W Busse, Nathan D Nielsen
BACKGROUND: Data to support the use of specific vasopressors in septic shock are limited. Since angiotensin II (AT2) was approved by the Food and Drug Administration in 2017, multiple mechanistically distinct vasopressors are available to treat septic shock, but minimal data exist regarding which patients are most likely to benefit from each agent. Renin and dipeptidyl peptidase 3 (DPP3) are components of the renin-angiotensin-aldosterone system which have been shown to outperform lactate in predicting sepsis prognosis, and preliminary data suggest they could prove useful as biomarkers to guide AT2 use in septic shock...
March 12, 2024: Trials
https://read.qxmd.com/read/38383521/angiotensin-ii-therapy-in-refractory-septic-shock-which-patient-can-benefit-most-a-narrative-review
#4
REVIEW
Irene Coloretti, Andrea Genovese, J Pedro Teixeira, Anusha Cherian, Ricard Ferrer, Giovanni Landoni, Marc Leone, Massimo Girardis, Nathan D Nielsen
Patients with septic shock who experience refractory hypotension despite adequate fluid resuscitation and high-dose noradrenaline have high mortality rates. To improve outcomes, evidence-based guidelines recommend starting a second vasopressor, such as vasopressin, if noradrenaline doses exceed 0.5 µg/kg/min. Recently, promising results have been observed in treating refractory hypotension with angiotensin II, which has been shown to increase mean arterial pressure and has been associated with improved outcomes...
February 21, 2024: J Anesth Analg Crit Care
https://read.qxmd.com/read/38303571/clinical-response-to-third-line-angiotensin-ii-vs-epinephrine-in-septic-shock-a-propensity-matched-cohort-study
#5
JOURNAL ARTICLE
Caitlyn R Blankenship, Kevin D Betthauser, Laura N Hencken, Julie A Maamari, Jenna Goetz, Bria D Giacomino, Gabrielle A Gibson
BACKGROUND: The appropriate third-line vasopressor in septic shock patients receiving norepinephrine and vasopressin is unknown. Angiotensin-II (AT-II) offers a unique mechanism of action to traditionally used vasopressors in septic shock. OBJECTIVE: The objective of this study was to compare the clinical efficacy and safety of third-line AT-II to epinephrine in patients with septic shock. METHODS: A single-center, retrospective cohort study of critically ill patients was performed between April 1, 2019 and July 31, 2022...
February 1, 2024: Annals of Pharmacotherapy
https://read.qxmd.com/read/38103056/angiotensin-ii-treatment-is-associated-with-improved-oxygenation-in-ards-patients-with-refractory-vasodilatory-shock
#6
JOURNAL ARTICLE
Daniel E Leisman, Damian R Handisides, Lakhmir S Chawla, Timothy E Albertson, Laurence W Busse, David W Boldt, Adam M Deane, Michelle N Gong, Kealy R Ham, Ashish K Khanna, Marlies Ostermann, Michael T McCurdy, B Taylor Thompson, James S Tumlin, Christopher D Adams, Tony N Hodges, Rinaldo Bellomo
BACKGROUND: The physiological effects of renin-angiotensin system modulation in acute respiratory distress syndrome (ARDS) remain controversial and have not been investigated in randomized trials. We sought to determine whether angiotensin-II treatment is associated with improved oxygenation in shock-associated ARDS. METHODS: Post-hoc subgroup analysis of the Angiotensin Therapy for High Output Shock (ATHOS-3) trial. We studied patients who met modified Berlin ARDS criteria at enrollment...
December 16, 2023: Annals of Intensive Care
https://read.qxmd.com/read/37986086/the-alternative-renin-angiotensin-system-in-critically-ill-patients-pathophysiology-and-therapeutic-implications
#7
REVIEW
Bruno Garcia, Alexander Zarbock, Rinaldo Bellomo, Matthieu Legrand
The renin-angiotensin system (RAS) plays a crucial role in regulating blood pressure and the cardio-renal system. The classical RAS, mainly mediated by angiotensin I, angiotensin-converting enzyme, and angiotensin II, has been reported to be altered in critically ill patients, such as those in vasodilatory shock. However, recent research has highlighted the role of some components of the counterregulatory axis of the classical RAS, termed the alternative RAS, such as angiotensin-converting Enzyme 2 (ACE2) and angiotensin-(1-7), or peptidases which can modulate the RAS like dipeptidyl-peptidase 3, in many critical situations...
November 20, 2023: Critical Care: the Official Journal of the Critical Care Forum
https://read.qxmd.com/read/37947484/association-of-active-renin-content-with-mortality-in-critically-ill-patients-a-post-hoc-analysis-of-the-vitamin-c-thiamine-and-steroids-in-sepsis-victas-trial
#8
JOURNAL ARTICLE
Laurence W Busse, Christopher L Schaich, Mark C Chappell, Michael T McCurdy, Erin M Staples, Caitlin C Ten Lohuis, Jeremiah S Hinson, Jonathan E Sevransky, Richard E Rothman, David W Wright, Greg S Martin, Ashish K Khanna
OBJECTIVE: Sepsis is a leading cause of mortality. Predicting outcomes is challenging and few biomarkers perform well. Defects in the renin-angiotensin system (RAS) can predict clinical outcomes in sepsis and may outperform traditional biomarkers. We postulated that RAS dysfunction (elevated active renin, angiotensin 1-7 [Ang-(1-7)], and angiotensin-converting enzyme 2 (ACE2) activity with depressed Ang-II and ACE activity) would be associated with mortality in a cohort of septic patients...
March 1, 2024: Critical Care Medicine
https://read.qxmd.com/read/37815234/prior-use-of-angiotensin-converting-enzyme-inhibitors-or-angiotensin-ii-receptor-blockers-and-clinical-outcomes-of-sepsis-and-septic-shock-a-systematic-review-and-meta-analysis
#9
JOURNAL ARTICLE
Dhan Bahadur Shrestha, Yub Raj Sedhai, Prakash Raj Oli, Ekaterina Proskuriakova, Alla Adelkhanova, Jurgen Shtembari, Tahir Muhammad Abdullah Khan, Karan Singh, Muhammad Altaf Ahmed, Irfan Waheed, Nisarfathima Kazimuddin, Rodney Steff, Roshan Acharya, Nimesh K Patel
Sepsis and septic shock are life-threatening conditions that are associated with high mortality and considerable health care costs. The association between prior angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARBs) use and outcomes after sepsis is elusive. The aim of this study was to evaluate the role of the prior use of ACEi or ARBs and outcomes after sepsis and septic shock. A relevant literature review was performed in 4 databases from inception until July 2022. Independent reviewers first screened the title, abstract, and full text, and then, data extraction and analysis were performed...
January 1, 2024: Journal of Cardiovascular Pharmacology
https://read.qxmd.com/read/37734468/micro-lightguide-spectrophotometry-assessment-of-hepatic-and-intestinal-microcirculation-in-endotoxemic-rats-during-intravenous-treatment-with-angiotensin-ii
#10
JOURNAL ARTICLE
Götz Schmidt, Laurenz Pitz, Melanie Markmann, Emmanuel Schneck, Michael Sander, Christian Koch, Fabian Edinger
INTRODUCTION: During septic shock, impairment of microcirculation leads to enhanced permeability of intestinal mucosa triggered by generalized vasodilation and capillary leak. Intravenous angiotensin II (AT-II) has been approved for the treatment of septic shock; however, no in-vivo data exist on the influence of AT-II on hepatic and intestinal microcirculation. MATERIAL AND METHODS: Sixty male Lewis rats were randomly assigned to six study groups (each n = 10): sham, lipopolysaccharide-induced septic shock, therapy with low- or high-dose AT-II (50 or 100 ng/kg/min, respectively), and septic shock treated with low- or high-dose AT-II...
September 19, 2023: European Journal of Pharmaceutical Sciences
https://read.qxmd.com/read/37547893/vasoplegia-a-review
#11
REVIEW
Iqbal Ratnani, Rohan Kumar Ochani, Asim Shaikh, Hafsa Nazir Jatoi
Vasoplegia is a condition characterized by persistent low systemic vascular resistance despite a normal or high cardiac index, resulting in profound and uncontrolled vasodilation. Vasoplegia may occur due to various conditions, including cardiac failure, sepsis, and post-cardiac surgery. In the cardiac cohort, multiple risk factors for vasoplegia have been identified. Several factors contribute to the pathophysiology of this condition, and various mechanisms have been proposed, including nitric oxide, adenosine, prostanoids, endothelins, the renin-angiotensin-aldosterone system, and hydrogen sulfide...
2023: Methodist DeBakey Cardiovascular Journal
https://read.qxmd.com/read/37546921/adjunctive-vasopressors-in-patients-with-septic-shock-protocol-for-a-systematic-review-and-meta-analysis
#12
Seth R Bauer, Patrick M Wieruszewski, Brittany D Bissell, Siddharth Dugar, Gretchen L Sacha, Ryota Sato, Matthew T Siuba, Mary Schleicher, Vidula Vachharajani, Yngve Falck-Ytter, Rebecca L Morgan
BACKGROUND: Over one-third of patients with septic shock have adjunctive vasopressors added to first-line vasopressors. However, no randomized trial has detected improved mortality with adjunctive vasopressors. Published systematic reviews and meta-analysis have sought to inform the use of adjunctive vasopressors, yet each published review has limitations that hinder its interpretation. This review aims to overcome the limitations of previous reviews by systematically synthesizing the direct evidence for adjunctive vasopressor therapy use in adult patients with septic shock...
July 30, 2023: medRxiv
https://read.qxmd.com/read/37529784/circulatory-shock-in-adults-in-emergency-department
#13
REVIEW
Ashok Kumar Pannu
Circulatory shock is a common condition that carries high morbidity and mortality. This review aims to update the critical steps in managing common types of shock in adult patients admitted to medical emergency and intensive care units. A literature review was performed by searching PubMed, EMBASE Ovid, and Cochrane Library, using the following search items: ("shock" OR "circulatory shock" OR "septic shock" OR "cardiogenic shock") AND ("management" OR "treatment" OR "resuscitation"). The review emphasizes prompt shock identification with tissue hypoperfusion, knowledge of the underlying pathophysiological mechanism, initial fluid resuscitation with balanced crystalloids, norepinephrine as the preferred vasopressor in septic and profound cardiogenic shock, and tailored intervention addressing specific etiologies...
2023: Turkish Journal of Emergency Medicine
https://read.qxmd.com/read/37354683/impact-of-the-angiotensin-converting-enzyme-ace-inhibitors-on-the-course-of-the-septic-shock-developed-during-covid-19-and-other-severe-respiratory-infections-in-presence-of-hyperferritinemia
#14
JOURNAL ARTICLE
M Rurua, L Ratiani, T Sanikidze, K Machvariani, E Pachkoria, G Ormocadze, I Mikadze, T Didbaridze
SARS-CoV-2 can cause sepsis regardless of the presence of secondary bacterial or fungal infections. The virus itself likely causes sepsis through a variety of possible mechanisms, including immune dysregulation, with respiratory dysfunction, which as a result of circulatory dysfunction leads to hypoxemia and metabolic acidosis. We conducted cohort study, comparing outcomes of 212 critically ill patients with Septic shock (134 men (63.3%) and 78 women (36.7%), with a mean age between 40-70 years) were evaluated, who were treated in the intensive care unit of First University Clinic during 2020-2021 years...
April 2023: Georgian Medical News
https://read.qxmd.com/read/37308975/increasing-angiotensin-converting-enzyme-concentrations-and-absent-angiotensin-converting-enzyme-activity-are-associated-with-adverse-kidney-outcomes-in-pediatric-septic-shock
#15
MULTICENTER STUDY
Naomi Pode-Shakked, Giovanni Ceschia, James E Rose, Stuart L Goldstein, Natalja L Stanski
BACKGROUND: Sepsis-induced endothelial dysfunction is proposed to cause angiotensin-converting enzyme (ACE) dysfunction and renin-angiotensin-aldosterone system (RAAS) derangement, exacerbating vasodilatory shock and acute kidney injury (AKI). Few studies test this hypothesis directly, including none in children. We measured serum ACE concentrations and activity, and assessed their association with adverse kidney outcomes in pediatric septic shock. METHODS: A pilot study of 72 subjects aged 1 week-18 years from an existing multicenter, observational study...
June 12, 2023: Critical Care: the Official Journal of the Critical Care Forum
https://read.qxmd.com/read/37212085/recombinant-angiotensin-ii-therapy-in-a-child-with-cardiac-dysfunction-and-pandoraea-and-candida-sepsis
#16
JOURNAL ARTICLE
Michael E Kim, Stuart L Goldstein, Meghan M Chlebowski
Recombinant angiotensin II is an emerging drug therapy for refractory hypotension. Its use is relevant to patients with disruption of the renin-angiotensin-aldosterone system denoted by elevated direct renin levels. We present a child that responded to recombinant angiotensin II in the setting of right ventricular hypertension and multi-organism septic shock.
May 22, 2023: Cardiology in the Young
https://read.qxmd.com/read/36852879/single-center-experience-with-the-seraph-100%C3%A2-microbind%C3%A2-affinity-blood-filter-in-patients-with-sars-cov-2-infection-and-septic-shock-at-a-military-treatment-facility
#17
JOURNAL ARTICLE
Steven Stoffel, Joshua Boster, Zachary Jarrett, Melissa Rosas, Arjun Kalra, Mai Nugyen, Michael Morris, Robert Walter
INTRODUCTION: Coronavirus disease 2019 (COVID-19) infection is characterized by a dysregulated inflammatory response, which may result in severe hemodynamic instability and septic shock. The Seraph-100® Microbind® Affinity Blood Filter is a commercially available extracorporeal pathogen absorbent device with the ability to bind pathogens and cytokines present within the blood. Our study aimed to evaluate the efficacy of the Seraph-100® for patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and septic shock...
February 28, 2023: Military Medicine
https://read.qxmd.com/read/36769331/host-derived-cytotoxic-agents-in-chronic-inflammation-and-disease-progression
#18
REVIEW
Jürgen Arnhold
At inflammatory sites, cytotoxic agents are released and generated from invading immune cells and damaged tissue cells. The further fate of the inflammation highly depends on the presence of antagonizing principles that are able to inactivate these host-derived cytotoxic agents. As long as the affected tissues are well equipped with ready-to-use protective mechanisms, no damage by cytotoxic agents occurs and resolution of inflammation is initiated. However, long-lasting and severe immune responses can be associated with the decline, exhaustion, or inactivation of selected antagonizing principles...
February 3, 2023: International Journal of Molecular Sciences
https://read.qxmd.com/read/36457089/a-plea-for-personalization-of-the-hemodynamic-management-of-septic-shock
#19
REVIEW
Daniel De Backer, Maurizio Cecconi, Michelle S Chew, Ludhmila Hajjar, Xavier Monnet, Gustavo A Ospina-Tascón, Marlies Ostermann, Michael R Pinsky, Jean-Louis Vincent
Although guidelines provide excellent expert guidance for managing patients with septic shock, they leave room for personalization according to patients' condition. Hemodynamic monitoring depends on the evolution phase: salvage, optimization, stabilization, and de-escalation. Initially during the salvage phase, monitoring to identify shock etiology and severity should include arterial pressure and lactate measurements together with clinical examination, particularly skin mottling and capillary refill time. Low diastolic blood pressure may trigger vasopressor initiation...
December 1, 2022: Critical Care: the Official Journal of the Critical Care Forum
https://read.qxmd.com/read/36287393/hydrocortisone-may-act-through-the-angiotensin-ii-receptor-2-level-in-patients-with-catecholamine-resistant-septic-shock
#20
JOURNAL ARTICLE
Seyma Baykan, Murat Bicakcioglu, Nilüfer Bulut, Neslihan Yucel, Yasemin Ersoy, Nermin Kibrislioglu Uysal, Ayse B Ozer
BACKGROUND: This study aimed to compare the serum angiotensin II and its receptor levels (AT1, AT2) in septic patients with catecholamine-responsive or resistant. The effect of hydrocortisone treatment on angiotensin II levels in the catecholamine-resistant septic patients was evaluated. METHODS: This prospective observational study enrolled 40 patients diagnosed with septic shock based on sepsis-3 criteria. Patients were divided into two groups according to the noradrenalin infusion rate required to keep the mean arterial pressure above 65 mmHg: Control Group and Hydrocortisone Group (control group: below 0...
October 26, 2022: Minerva Anestesiologica
keyword
keyword
169992
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.